Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED

Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Module 1 of this continuing pharmacy education (CPE)"approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.

TARGET AUDIENCE

Managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, pharmacists, and other health care professionals involved in the case management of patients with newly diagnosed multiple myeloma (NDMM).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Assess guideline-recommended treatment combination and sequencing strategies for NDMM
Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM"